Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus whole-brain radiotherapy for brain metastases from lung cancer
CTR20230452Phase 2Completed
- Sponsor
- Tianjin Xinyi Shangde Biomedical Technology
- Start
- Apr 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchial carcinoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) comparing ACT001 + whole-brain radiotherapy with Placebo + whole-brain radiotherapy (2 arms). Primary endpoint: Intracranial objective response rate at 3 months. Started Apr 2023; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
bronchial carcinomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230452.